The EBAG9 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the EBAG9 gene in a well-established human cervical adenocarcinoma background. This polyclonal pool contains heterogeneous gene disruptions across the cell population, providing a genetically diverse model to assess EBAG9 function. The knockout was generated via CRISPR/Cas9-mediated gene disruption, resulting in a versatile tool for investigating the role of EBAG9 in immune evasion and apoptosis regulation without relying on single-cell-clone artifacts.
The host cell line HeLa is an immortalized epithelial cell line derived from human cervical adenocarcinoma, widely utilized in cancer research due to its robust growth and genetic tractability. HeLa cells harbor HPV18 integration, leading to inactivation of the tumor suppressors p53 and Rb, which contributes to their transformed phenotype. This background provides a relevant context for studying oncogenic processes, particularly those involving immune modulation and tumor?Cimmune interactions.
EBAG9 encodes the tumor-associated antigen RCAS1, a ligand that engages an uncharacterized receptor on T lymphocytes and natural killer (NK) cells to induce apoptosis, thereby facilitating immune escape. Mechanistically, RCAS1 binding triggers caspase activation and cytochrome c release, with modulation by Bcl-2 family members. Upstream, EBAG9 expression is transcriptionally activated by estrogen signaling through the estrogen receptor and SP1 transcription factor, linking hormone responsiveness to tumor immune privilege. Thus, EBAG9 operates at the intersection of apoptosis, immune response, and estrogen signaling pathways.
In HeLa cells, which express viral oncoproteins that subvert apoptosis and cell cycle control, EBAG9 knockout permits dissection of additional immune evasion mechanisms employed by cervical cancer cells. The polyclonal nature of the knockout population mirrors the heterogeneity of tumor cell phenotypes, enabling studies of how varying levels of RCAS1 loss affect interactions with immune effector cells. This model is particularly suited for examining the interplay between estrogen-driven gene expression and tumor?Cimmune communication in a cervical cancer context.
Researchers can employ these polyclonal knockout cells in co-culture apoptosis assays with peripheral blood mononuclear cells (PBMCs) to measure T cell and NK cell killing resistance, followed by flow cytometric analysis of Annexin V/PI staining. Western blotting for RCAS1 verifies protein ablation, while estrogen response element reporter assays probe transcriptional regulation. Cytotoxicity assays and T cell proliferation inhibition studies further elucidate the functional impact of EBAG9 loss on immune evasion, making this product valuable for cancer immunotherapy target validation and immune checkpoint research. For technical inquiries, please contact Ascent Research.
